Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
Abstract
The synthesis and structure-activity relationship of a novel series of compounds with combined effects on 5-HT(3A) and 5-HT(1A) receptors and on the serotonin (5-HT) transporter (SERT) are described. Compound 5m (Lu AA21004) was the lead compound, displaying high affinity for recombinant human 5-HT(1A) (K(i) = 15 nM), 5-HT(1B) (K(i) = 33 nM), 5-HT(3A) (K(i) = 3.7 nM), 5-HT(7) (K(i) = 19 nM), and noradrenergic β(1) (K(i) = 46 nM) receptors, and SERT (K(i) = 1.6 nM). Compound 5m displayed antagonistic properties at 5-HT(3A) and 5-HT(7) receptors, partial agonist properties at 5-HT(1B) receptors, agonistic properties at 5-HT(1A) receptors, and potent inhibition of SERT. In conscious rats, 5m significantly increased extracellular 5-HT levels in the brain after acute and 3 days of treatment. Following the 3-day treatment (5 or 10 (mg/kg)/day) SERT occupancies were only 43% and 57%, respectively. These characteristics indicate that 5m is a novel multimodal serotonergic compound, and 5m is currently in clinical development for major depressive disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The in vivo nonclinical studies in rodents have demonstrated that vortioxetine modulates serotonergic, noradrenergic, dopaminergic, cholinergic, histaminergic, and glutamatergic neurotransmission, affecting the levels of neurotransmitters involved in cognitive processes (Bang-Andersen et al, 2011; Mork et al, 2012, 2013; Pehrson et al, 2013; Pehrson and Sanchez, 2014; Wallace et al, 2014).”
From A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder (2015) · cites this paper as Bang-Andersen et al, 2011
In the citing paper
“The antidepressant vortioxetine, developed by Lundbeck and Takeda and approved in 2013, is a 5-HT 3 , 5-HT 7 and 5-HT 1D receptor antagonist, a 5-HT 1B receptor partial agonist, a 5-HT 1A receptor agonist and an inhibitor of the 5-HT transporter (Bang-Andersen et al., 2011) with a good tolerability and long-term safety profile and no evidence of sexual dysfunction as a side effect.”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Bang-Andersen et al., 2011
In the citing paper
“Vortioxetine (Lu AA21004) is an antidepressant that acts as an antagonist of the 5-HT3 and 5-HT7 serotonin receptors, partial agonist of the 5-HT1B serotonin receptor, agonist of the 5-HT1A receptor, and inhibits the serotonin transporter [88].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [88]
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
Fanselow, M. S., & Dong, H.-W. (2010) · Neuron · doi:10.1016/j.neuron.2009.11.031 · Cited by 3,358
Drevets, W. C., Price, J. L., & Furey, M. L. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0189-x · Cited by 2,241
Evidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
Morphy, R., & Rankovic, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,209
A Simple Catalytic Method for the Conversion of Aryl Bromides to Arylamines
Guram, A. S., Rennels, R. A., & Buchwald, S. L. (1995) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199513481 · Cited by 1,070
Louie, J., & Hartwig, J. F. (1995) · Tetrahedron Letters · doi:10.1016/0040-4039(95)00605-c · Cited by 914
Is there a role for 5-HT1A agonists in the treatment of depression?
Blier, P., & Ward, N. M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01643-8 · Cited by 529
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Research works printed but not linked: 3
- Lenox R. H., 2002, Neuropsychopharmacology: The Fifth Generation of Progress: An Official Publication of the American College of Neuropsychopharmacology, 1139
- Moore N. A., 2008, Neuropsychopharmacology, 18, S321, 10.1016/s0924-977x(08)70440-1 · DOI
- Brunello N., 2003, Int. Clin. Psychopharmacol., 18, 191, 10.1097/01.yic.0000073880.93678.68 · doi:10.1097/01.yic.0000073880.93678.68 · Paper page
Cited by
Items 501–600 of 628
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.012
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.027
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.036
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0147
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.085
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.087
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.040
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.076
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0120
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.010
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0148
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.069
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0149
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.060
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0144
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.072
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.050
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.053
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.033
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.059
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.056
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.096
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0132
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.099
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.025
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.022
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.030
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.023
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0143
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.068
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.041
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.092
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.004
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0134
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.067
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0152
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.039
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.047
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.065
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.084
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.002
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.057
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0109
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0125
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.013
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.003
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.079
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.091
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.042
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.006
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.038
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0139
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.005
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.100
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.110
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.119
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.146
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.113
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.101
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.115
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.126
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.111
Index by Use: Commonly Prescribed For (bold for FDA approved)
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.155
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.121
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.114
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.141
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.118
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.116
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.151
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.104
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.136
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.137
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.102
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.127
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.140
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.117
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.133
18-Year-old who attempted suicide by ingesting 300 mg of vortioxetine: A case report
Hachem, S., & Chaaban, T. A. (2022) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2022.100038
Deb, S. S., Roy, M., Limbu, B., & Bertelli, M. O. (2022) · Autism and child psychopathology series · doi:10.1007/978-3-030-88538-0_50 · Cited by 1
Role of HDAC5 and SIRT2 in depression and clinical efficacy of antidepressants
Cortés-Erice, M. (2022) · Depósito Académico Digital Universidad de Navarra (University of Navarra) · doi:10.15581/10171/64991
Yang, S.-T., An, Q., Cao, C.-F., Kuang, J.-Q., Li, M., & Ji, L.-L. (2023) · Research Square · doi:10.21203/rs.3.rs-3029489/v1
5-HT3 receptors in GtoPdb v.2023.3
Barnes, N. M., Hales, T. G., Lummis, S. C. R., Niesler, B., & Peters, J. A. (2023) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f68/2023.3
Stahl, S. M. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009464772.151
Mufti, A. A., Mughal, H., Azeemi, M. U. H., Kamal, M. A., Rabbani, F., Mufti, K. A., Sultan, S. M., Ahmad, B. I., Nawaz, Z., Afridi, A., et al. (2023) · Journal of Pakistan Psychiatric Society · doi:10.63050/jpps.20.04.281
Desfossés, C. Y., & Blier, P. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as16
Visible light–driven organic synthesis under other miscellaneous photocatalysis
Brahmachari, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95893-6.00003-7
Medications for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
Park, S., & Shen, W. W. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_133
Karacık, M., & Aksöz, B. E. (2024) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.33483/jfpau.1487644
Adverse Events of Eye Disorders Related to the Use of Vortioxetine: A Disproportionality Analysis
Duman, N. Ç. (2025) · Medical Records · doi:10.37990/medr.1640988
Effect of Vortioxetine on Pilocarpine Induced Status Epilepticus in Sprague Dawley Rats
Hegde, S., Sharath Kumar, C., Parida, A., Sandhu, J. S., & Manju, V. (2025) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.15.2.33
Pharmacological breakthroughs in anxiety management: exploring traditional and emerging therapies
Rajesham, V. V., Nandini, A. S., Nandini, A. S., Behera, A., & Rao, T. R. (2025) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20253381
Catatonia e estupor em paciente adulto
Junhan, V. S., Filho, C. H. O. M., dos Santos, G. N., & Henriques, G. C. (2025) · Caminhos da Clínica · doi:10.47385/camclin.5113.4.2025
Vardanyan, R., & Vardanyan, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33869-4.00043-0
Bruzos-Cidón, C., Llamosas, N., Bengoetxea, H., Lafuente, J. V., Ugedo, L., & Torrecilla, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.05.697635
Kumar, A., Kumari, S., Verma, A. K., Kumar, A., & Pradhan, R. K. (2025) · Student s Journal of Health Research Africa · doi:10.51168/sjhrafrica.v6i12.2458
Sequenced treatment alternatives to relieve adolescent depression: A pragmatic clinical trial
He, Y., Xian, Y., Li, X., Qiu, T., Jiang, X., Wang, T., Wen, Y., Qin, B., Teng, T., Li, Y., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121511
Korkmaz, E. (2023) · Dspace Repository (Marmara Üniversitesi)
Kammerer, M. H., Hasler, G., Hochstrasser, B., Baumann, A., & Sousek, A. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-026-01537-z
“Vortioxetine has multimodal activity in the central nervous system [10, 11].”
Kulynych, H. B. (2026) · Art of Medicine · doi:10.21802/artm.2026.1.37.55
Metadata
- Authors
- Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., & Stensbøl, T. B.
- Affiliations
- Neuroscience Drug Discovery Denmark, H. Lundbeck A/S, 9 Ottiliavej, DK-2500 Copenhagen-Valby, Denmark
- Lundbeck (Denmark) (DK)
- Lundbeck (United States) (US)
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-04-12
- Volume
- 54
- Issue
- 9
- Pages
- 3206-3221
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2036812642
- Cited by
- 606
- References
- 58
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 24 · 2023: 33 · 2022: 27 · 2021: 27 · 2020: 181 · 2019: 32 · 2018: 21 · 2017: 37 · 2016: 37 · 2015: 53 · 2014: 35 · 2013: 25 · 2012: 21
- FWCI
- 21.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- vortioxetine, major depressive disorder, multimodal antidepressant, 5-HT3 receptor antagonists, 5-HT1A receptor, 5-HT1B receptor, 5-HT7 receptor, serotonin transporter inhibition, structure-activity relationship, piperazine derivatives
- MeSH terms
- Vortioxetine, Animals, Antidepressive Agents, Cell Line, Major Depressive Disorder, Depressive Disorder, Major, Drug Stability, Hippocampus, Humans, Microsomes, Liver, Oocytes, Piperazines, Radioligand Assay, Receptors, Serotonin, Recombinant Proteins, Serotonin, Structure-Activity Relationship, Sulfides, Xenopus, Selective Serotonin Reuptake Inhibitors, Receptors, Serotonin, 5-HT1, Receptor, Serotonin, 5-HT1A, Receptor, Serotonin, 5-HT2C, Receptors, Serotonin, 5-HT3, Serotonin Plasma Membrane Transport Proteins, Rats, Drug Partial Agonism, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT3 Receptor Antagonists, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.